Výsledky vyhledávání - "Setsuo Takeda"

Preliminary study on the optimal dosage schedule for oral tegafur/uracil (UFT) chemotherapy

Autor: Sotaro Sadahiro, Hiroyasu Makuuchi, Nobuhiro Tokunaga, Setsuo Takeda, Norio Unemi, Junji Uchida, Masaya Mukai, Tomoo Tajima, Hiroyuki Okabe, Masahiko Yoshida

Publikováno v: International Journal of Clinical Oncology. 3:7-12

We evaluated a new dose-intensive schedule for oral UFT (tegafur and uracil in a molar ratio of 1:4) administered for 5 consecutive days followed by 2 drug-free days (weekly-5-method), in comparison with conventional daily administration (weekly-7 me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4af7213a9e7fb7934b97dd328c6072a
https://doi.org/10.1007/bf02490095

Zobrazit plný text záznamu

ChemInform Abstract: Synthesis and Antitumor Activities of 5′-O-Aminoacyl-3′-O-benzyl Derivatives of 2′-Deoxy-5-fluorouridine and Related Compounds

Autor: Yukio Tada, Atsuhiko Uemura, Uchida Junji, Junichi Yamashita, Setsuo Takeda

Publikováno v: ChemInform. 27

Various O-alkyl derivatives of 2'-deoxy-5-fluorouridine (FUdR) were synthesized and their antitumor activities in mice bearing sarcoma 180 (s.c.-p.o.) were evaluated in terms of the ED50 values (mg/kg/d). Most of these compounds were superior to FUdR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::590ae58f3b5a6836930693801bd21c3d
https://doi.org/10.1002/chin.199630284

Zobrazit plný text záznamu

Antitumor Agents. I. DNA Topoisomerase II Inhibitory Activity and the Structural Relationship of Podophyllotoxin Derivatives as Antitumor Agents

Autor: Fujimoto Katsuhiko, Takashi Kobunai, Konstanty Wierzba, Junichi Yamashita, Makoto Nomura, Setsuo Takeda, Tadafumi Terada, Yuji Yamada, Hideo Yamaguchi

Publikováno v: Chemical and Pharmaceutical Bulletin. 40:2720-2727

Various podophyllotoxin derivatives from desoxypodophyllotoxin (DPT) were synthesized to examine the structural relationships between the biological significance (cytotoxic effect, effects on DNA topoisomerase II and tubulin polymerization) in vitro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c51d5350849868e229f80fb3864a0c4e
https://doi.org/10.1248/cpb.40.2720

Zobrazit plný text záznamu

Potentiation of the antitumor activity of 5-trifluoromethyl-2?-deoxyuridine by the use of depot forms of the parent compound

Autor: Hiroshi Matsumoto, Hiroyasu Satake, Norio Unemi, Yusuke Wataya, Hikoya Hayatsu, Setsuo Takeda, Junichi Yamashita, Yuji Yamada, Konstanty Wierzba

Publikováno v: Cancer Chemotherapy and Pharmacology. 30:360-364

5-Trifluoromethyl-2'-deoxyuridine (CF3dUrd), an antitumor agent, is known to be short-lived in human plasma. Since its rapid elimination from the bloodstream seems to have descouraged the clinical evaluation of this drug, we explored the potential us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e8cf8d376fcf157a14eac663572190
https://doi.org/10.1007/bf00689963

Zobrazit plný text záznamu

Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2?-deoxyuridine derivative

Autor: Yuji Yamada, Hikoya Hayatsu, Junji Uchida, Norio Unemi, Hiroyasu Satake, Hitoshi Saito, Setsuo Takeda, Junichi Yamashita, Yusuke Wataya

Publikováno v: Cancer Chemotherapy and Pharmacology. 29:122-126

1-(3-O-Benzyl-2-deoxy-beta-D-ribofuranosyl)-5-trifluoromethyl-2,4(1H,3)- pyrimidinedione (FTC-092), a fluorinated pyrimidine derivative, appeared to be effective against various transplantable tumors in mice following oral administration, and its act

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189663407dd17fd02fc1082d132bb5dd
https://doi.org/10.1007/bf00687321

Zobrazit plný text záznamu

Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts

Autor: Shin, Nakahira, Shoji, Nakamori, Masanori, Tsujie, Setsuo, Takeda, Keishi, Sugimoto, Yuji, Takahashi, Jiro, Okami, Shigeru, Marubashi, Atsushi, Miyamoto, Yutaka, Takeda, Hiroaki, Nagano, Keizo, Dono, Koji, Umeshita, Masato, Sakon, Morito, Monden

Publikováno v: Anticancer research. 28(1A)

The systemic administration of gemcitabine (GEM) has been accepted as a standard treatment for patients with advanced pancreatic cancer. The major mediator of cellular uptake of GEM is the human equilibrative nucleoside transporter 1 (hENT1) whose ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::aa6918fca2d37667fa77b2d29dcb11dd
https://pubmed.ncbi.nlm.nih.gov/18383843

Zobrazit plný text záznamu

Menogaril, an Anthracycline Compound with a Novel Mechanism of Action: Cellular Pharmacology

Autor: Setsuo Takeda, Toshiyuki Toko, Yoshikazu Sugimoto, Konstanty Wierzba, Shigeru Tsukagoshi, Yuji Yamada, Ken‐ichi ‐i Matsuo

Publikováno v: Japanese Journal of Cancer Research : Gann

Menogaril, an anthracycline compound possessing a significant antitumor activity after both po and iv administration, has been introduced into clinical trials. However, its mechanism of action has not been clarified yet. This study revealed that its

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7877bf9ff62946d656709af2d471fb
http://europepmc.org/articles/PMC5918082

Zobrazit plný text záznamu

Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model

Autor: Keizo Dono, Masato Sakon, Setsuo Takeda, Jiro Okami, Masanori Tsujie, Shoji Nakamori, Hiroaki Nagano, Morito Monden, Nobuyasu Hayashi, Shin Nakahira, Koji Umeshita, Yuji Takahashi

Publikováno v: Pancreas. 33(2)

Objectives Gemcitabine is taken up by cells mainly via human equilibrative nucleoside transporter 1 (hENT1). Pretreatment of cancer cell lines with 5-fluorouracil (5-FU) leads to an increase in the expression of hENT1 and augments the effect of singl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::231214c1e401aca6ac52dab6508f519d
https://pubmed.ncbi.nlm.nih.gov/16868479

Zobrazit plný text záznamu

Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats

Autor: Norio Unemi, Junji Uchida, Setsuo Takeda, Akira Mita, Kisako Toko, Teiji Takechi, Koushi Nakano, Tetsuhiko Shirasaka

Publikováno v: Cancer chemotherapy and pharmacology. 39(3)

S-1, a new oral antitumor agent, is composed of 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur, FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. FT which is a masked compound of 5-fluorouracil (5-FU)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::087a859bf36efb3b0f7b0251be4f0575
https://pubmed.ncbi.nlm.nih.gov/8996521

Zobrazit plný text záznamu

Synthesis and antitumor activities of 5'-O-aminoacyl-3'-O-benzyl derivatives of 2'-deoxy-5-fluorouridine and related compounds

Autor: Yukio Tada, Junichi Yamashita, Atsuhiko Uemura, Uchida Junji, Setsuo Takeda

Publikováno v: Chemicalpharmaceutical bulletin. 44(1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b4f059a3551140ed56802d86d41fbeb
https://pubmed.ncbi.nlm.nih.gov/8582036

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání